SPDR S&P Biotech ETF Key Executives
This section highlights SPDR S&P Biotech ETF's key executives, including their titles and compensation details.
Find Contacts at SPDR S&P Biotech ETF
( total contacts)
SPDR S&P Biotech ETF Earnings
This section highlights SPDR S&P Biotech ETF's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Financial Statements
Access annual & quarterly financial statements for SPDR S&P Biotech ETF, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown |
|---|
| Revenue |
| Cost of Revenue |
| Gross Profit |
| Gross Profit Ratio |
| Research and Development Expenses |
| General and Administrative Expenses |
| Selling and Marketing Expenses |
| Selling General and Administrative Expenses |
| Other Expenses |
| Operating Expenses |
| Cost and Expenses |
| Interest Income |
| Interest Expense |
| Depreciation and Amortization |
| EBITDA |
| EBITDA Ratio |
| Operating Income |
| Operating Income Ratio |
| Total Other Income Expenses Net |
| Income Before Tax |
| Income Before Tax Ratio |
| Income Tax Expense |
| Net Income |
| Net Income Ratio |
| EPS |
| EPS Diluted |
| Weighted Average Shares Outstanding |
| Weighted Average Shares Outstanding Diluted |
| SEC Filing |
| Breakdown |
|---|
| Revenue |
| Cost of Revenue |
| Gross Profit |
| Gross Profit Ratio |
| Research and Development Expenses |
| General and Administrative Expenses |
| Selling and Marketing Expenses |
| Selling General and Administrative Expenses |
| Other Expenses |
| Operating Expenses |
| Cost and Expenses |
| Interest Income |
| Interest Expense |
| Depreciation and Amortization |
| EBITDA |
| EBITDA Ratio |
| Operating Income |
| Operating Income Ratio |
| Total Other Income Expenses Net |
| Income Before Tax |
| Income Before Tax Ratio |
| Income Tax Expense |
| Net Income |
| Net Income Ratio |
| EPS |
| EPS Diluted |
| Weighted Average Shares Outstanding |
| Weighted Average Shares Outstanding Diluted |
| SEC Filing |
Annual Balance Sheet
| Breakdown |
|---|
| Cash and Cash Equivalents |
| Short Term Investments |
| Cash and Short Term Investments |
| Net Receivables |
| Inventory |
| Other Current Assets |
| Total Current Assets |
| Property Plant Equipment Net |
| Goodwill |
| Intangible Assets |
| Goodwill and Intangible Assets |
| Long Term Investments |
| Tax Assets |
| Other Non-Current Assets |
| Total Non-Current Assets |
| Other Assets |
| Total Assets |
| Account Payables |
| Short Term Debt |
| Tax Payables |
| Deferred Revenue |
| Other Current Liabilities |
| Total Current Liabilities |
| Long Term Debt |
| Deferred Revenue Non-Current |
| Deferred Tax Liabilities Non-Current |
| Other Non-Current Liabilities |
| Total Non-Current Liabilities |
| Other Liabilities |
| Total Liabilities |
| Preferred Stock |
| Common Stock |
| Retained Earnings |
| Accumulated Other Comprehensive Income Loss |
| Other Total Stockholders Equity |
| Total Stockholders Equity |
| Total Equity |
| Total Liabilities and Stockholders Equity |
| Minority Interest |
| Total Liabilities and Total Equity |
| Total Investments |
| Total Debt |
| Net Debt |
Balance Sheet Charts
| Breakdown |
|---|
| Cash and Cash Equivalents |
| Short Term Investments |
| Cash and Short Term Investments |
| Net Receivables |
| Inventory |
| Other Current Assets |
| Total Current Assets |
| Property Plant Equipment Net |
| Goodwill |
| Intangible Assets |
| Goodwill and Intangible Assets |
| Long Term Investments |
| Tax Assets |
| Other Non-Current Assets |
| Total Non-Current Assets |
| Other Assets |
| Total Assets |
| Account Payables |
| Short Term Debt |
| Tax Payables |
| Deferred Revenue |
| Other Current Liabilities |
| Total Current Liabilities |
| Long Term Debt |
| Deferred Revenue Non-Current |
| Deferred Tax Liabilities Non-Current |
| Other Non-Current Liabilities |
| Total Non-Current Liabilities |
| Other Liabilities |
| Total Liabilities |
| Preferred Stock |
| Common Stock |
| Retained Earnings |
| Accumulated Other Comprehensive Income Loss |
| Other Total Stockholders Equity |
| Total Stockholders Equity |
| Total Equity |
| Total Liabilities and Stockholders Equity |
| Minority Interest |
| Total Liabilities and Total Equity |
| Total Investments |
| Total Debt |
| Net Debt |
Annual Cash Flow
| Breakdown |
|---|
| Net Income |
| Depreciation and Amortization |
| Deferred Income Tax |
| Stock Based Compensation |
| Change in Working Capital |
| Accounts Receivables |
| Inventory |
| Accounts Payables |
| Other Working Capital |
| Other Non Cash Items |
| Net Cash Provided by Operating Activities |
| Investments in Property Plant and Equipment |
| Acquisitions Net |
| Purchases of Investments |
| Sales Maturities of Investments |
| Other Investing Activities |
| Net Cash Used for Investing Activities |
| Debt Repayment |
| Common Stock Issued |
| Common Stock Repurchased |
| Dividends Paid |
| Other Financing Activities |
| Net Cash Used Provided by Financing Activities |
| Effect of Forex Changes on Cash |
| Net Change in Cash |
| Cash at End of Period |
| Cash at Beginning of Period |
| Operating Cash Flow |
| Capital Expenditure |
| Free Cash Flow |
Cash Flow Charts
| Breakdown |
|---|
| Net Income |
| Depreciation and Amortization |
| Deferred Income Tax |
| Stock Based Compensation |
| Change in Working Capital |
| Accounts Receivables |
| Inventory |
| Accounts Payables |
| Other Working Capital |
| Other Non Cash Items |
| Net Cash Provided by Operating Activities |
| Investments in Property Plant and Equipment |
| Acquisitions Net |
| Purchases of Investments |
| Sales Maturities of Investments |
| Other Investing Activities |
| Net Cash Used for Investing Activities |
| Debt Repayment |
| Common Stock Issued |
| Common Stock Repurchased |
| Dividends Paid |
| Other Financing Activities |
| Net Cash Used Provided by Financing Activities |
| Effect of Forex Changes on Cash |
| Net Change in Cash |
| Cash at End of Period |
| Cash at Beginning of Period |
| Operating Cash Flow |
| Capital Expenditure |
| Free Cash Flow |
SPDR S&P Biotech ETF (XBI)
In seeking to track the performance of the S&P Biotechnology Select Industry Index (the "index"), the fund employs a sampling strategy. It generally invests substantially all, but at least 80%, of its total assets in the securities comprising the index. The index represents the biotechnology segment of the S&P Total Market Index ("S&P TMI").
$77.55
Stock Price
$5.18B
Market Cap
-
Employees
Boston, MA
Location
Revenue (FY )
$-
% YoY
Net Income (FY )
$-
% YoY
EPS (FY )
$
% YoY
Free Cash Flow (FY )
$-
% YoY
Profitability
Gross Margin
%
Net Margin
%
ROE
%
ROA
%
Valuation
P/E Ratio
P/S Ratio
EV/EBITDA
Market Cap
$5.18B
Revenue & Net Income
Profit Margins
Cash Flow Summary
Operating Cash Flow
$-
% YoY
Free Cash Flow
$-
% YoY
Balance Sheet Summary
Total Assets
$-
% YoY
Total Debt
$-
0.0% YoY
Shareholder Equity
$-
% YoY
Dividend Overview
$0.01
Latest Dividend
%
Dividend Yield
%
Payout Ratio
Recent Dividend History
| Date | Amount | Type |
|---|---|---|
| 2025-03-24 | $0.01 | March 24, 25 |
| 2024-12-23 | $0.00 | December 23, 24 |
| 2024-09-23 | $0.02 | September 23, 24 |
| 2024-06-24 | $0.11 | June 24, 24 |
| 2023-12-18 | $0.01 | December 18, 23 |
| 2023-06-20 | $0.00 | June 20, 23 |
| 2021-03-22 | $0.04 | March 22, 21 |
| 2020-12-21 | $0.18 | December 21, 20 |
| 2020-09-21 | $0.09 | September 21, 20 |
| 2020-06-22 | $0.02 | June 22, 20 |
SPDR S&P Biotech ETF Dividends
Explore SPDR S&P Biotech ETF's dividend history, including dividend yield, payout ratio, and historical payments.
Dividend Yield
-
Dividend Payout Ratio
-
Dividend Paid & Capex Coverage Ratio
x
SPDR S&P Biotech ETF Dividend History
| Dividend | Adjusted Dividend | Date | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|
| $0.00525 | $0.00525 | March 24, 2025 | March 24, 2025 | March 26, 2025 | January 09, 2025 |
| $0.002687 | $0.002687 | December 23, 2024 | December 23, 2024 | December 26, 2024 | |
| $0.015228 | $0.015228 | September 23, 2024 | September 23, 2024 | September 25, 2024 | January 02, 2024 |
| $0.11478 | $0.11478 | June 24, 2024 | June 24, 2024 | June 26, 2024 | January 02, 2024 |
| $0.013877 | $0.013877 | December 18, 2023 | December 19, 2023 | December 21, 2023 | January 17, 2023 |
| $0.00262 | $0.00262 | June 20, 2023 | June 21, 2023 | June 23, 2023 | January 17, 2023 |
| $0.04 | $0.04 | March 22, 2021 | March 23, 2021 | March 25, 2021 | January 21, 2021 |
| $0.176 | $0.176 | December 21, 2020 | December 22, 2020 | December 24, 2020 | January 15, 2020 |
| $0.089 | $0.088967 | September 21, 2020 | September 22, 2020 | September 24, 2020 | January 15, 2020 |
| $0.017 | $0.016758 | June 22, 2020 | June 23, 2020 | June 25, 2020 | January 15, 2020 |
| $0.000857 | $0.000857 | December 20, 2019 | December 23, 2019 | December 26, 2019 | |
| $0.003 | $0.003187 | September 20, 2019 | September 23, 2019 | September 25, 2019 | January 11, 2019 |
| $0.012 | $0.01196 | December 21, 2018 | December 24, 2018 | December 27, 2018 | January 11, 2018 |
| $0.073 | $0.072612 | September 21, 2018 | September 24, 2018 | September 26, 2018 | January 11, 2018 |
| $0.058 | $0.05849 | June 15, 2018 | June 18, 2018 | June 20, 2018 | June 14, 2018 |
| $0.059 | $0.059081 | March 16, 2018 | March 19, 2018 | March 21, 2018 | January 11, 2018 |
| $0.035 | $0.03473 | December 15, 2017 | December 18, 2017 | December 26, 2017 | December 14, 2017 |
| $0.037 | $0.03704 | September 15, 2017 | September 18, 2017 | September 25, 2017 | September 14, 2017 |
| $0.11 | $0.11014 | June 16, 2017 | June 20, 2017 | June 26, 2017 | June 16, 2017 |
| $0.02 | $0.019702 | March 17, 2017 | March 21, 2017 | March 27, 2017 |
SPDR S&P Biotech ETF News
Read the latest news about SPDR S&P Biotech ETF, including recent articles, headlines, and updates.
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - Yet
President Trump has announced today he plans to reduce U.S. drug prices by 30-80% via an Executive Order, targeting Big Pharma's high costs and profits. U.S. drug prices are significantly higher (up to ten time more in some cases) than in other countries due to, e.g., R&D costs, direct-to-consumer marketing, and pharmacy benefit managers. Despite Trump's aggressive stance, Pharma stocks have risen in trading today, suggesting investors believe negotiations will soften his initial hardline approach.
Drug stocks sink as FDA's top vaccine official is ousted in Trump overhaul
Shares of U.S. drugmakers fell on Monday after reports that the Food and Drug Administration's top vaccine official was forced to resign, the most high-profile exit at the regulator as the Trump administration undertakes an overhaul of federal health agencies.
Invest In A New Biotech Bull Market With XBI And IBB
Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides more leverage to the biotech turnaround trade. Falling interest rates, weak GDP growth, low inflation, and Fed rate cuts mean the macro environment is ripe for biotech.
XBI: Diverse Holding Amid Strong Catalysts, Buy
SPDR® S&P Biotech ETF is a strong investment due to rising demand for biotech solutions addressing chronic diseases and its diverse, equal-weighted portfolio. XBI's equal-weighting strategy reduces concentration risk and balances risk-reward by investing in large, mid, and small-cap biotech companies. Strong industry trends and government support, including increasing NIH funding, bolster XBI's long-term growth potential despite short-term volatility from RFK's appointment.
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Top 5 Cancer Pharma Stocks With Strong Risk/Reward In 2025
This article will provide an in-depth analysis of drugs being developed to combat cancer. Big Pharma is keenly interested in the global cancer therapeutics market, which is expected to exceed $400 billion by 2028. Every year, the FDA and EMA approve dozens of anticancer drugs, so Seeking Alpha readers should be careful when making decisions.
3 Oversold Biotech Names
High beta market sectors, including small caps and biotech, sold off significantly last week as the 10-Year Treasury yield surpassed 4.75%. The JP Morgan Healthcare event in San Francisco that opens today and runs through most of the week could boost sentiment on the biotech sector. In the paragraphs below, I highlight three biotech/biopharma names that appear oversold at current trading levels.
Finding Winners In Biotech, Probably The Riskiest Sector
Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year clinical and commercial momentum, diversifying with multiple drug candidates.
Is Biotech's Bull Run Over? Examining Election Impacts
The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.
Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)
Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leading the HHS are likely overblown; his confirmation is uncertain, and his focus may impact the food sector more than biotech. The biotech sector appears oversold with little “froth,” especially compared to the overall market, suggesting a buying opportunity for long-term investors.
XBI: Biotech ETF Is A Must Have
SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the Russell 2000, not the S&P 500, due to its heavy focus on small- and mid-cap stocks. I believe that economic conditions are favorable for growth in the biotechnology sector, despite the recent spike in over 20-year Treasury bond yields.
3 Attractive Biotechs With Recent Positives
The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.
3 'Repeatable' Biotech Trades
Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for XBI.